A multicentre blinded study to evaluate KRAS mutation testing methodologies in the clinical setting

V. Whitehall, K. Tran, A. Umapathy, F. Grieu, C. Hewett, T.J. Evans, W.Q. Li, T.M. Ismail, P. Collins, P. Ravetto, S. Fox, M. Salto-Tellez, R. Soong, B. Leggett, R.J. Scott, A. Dobrovic, Barry Iacopetta

    Research output: Contribution to journalArticle

    110 Citations (Scopus)

    Abstract

    Evidence that activating mutations of the KRAS oncogene abolish the response to anti-epidermal growth factor receptor therapy has revolutionized the treatment of advanced colorectal cancer. This has resulted in the urgent demand for KRAS mutation testing in the clinical setting to aid choice of therapy. The aim of this study was to evaluate six different KRAS mutation detection methodologies on two series of primary colorectal cancer samples. Two series of 80 frozen and 74 formalin-fixed paraffin-embedded tissue samples were sourced and DNA was extracted at a central site before distribution to seven different testing sites. KRAS mutations in codons 12 and 13 were assessed by using single strand conformation polymorphism analysis, pyrosequencing, high resolution melting analysis, dideoxy sequencing, or the commercially available TIB Molbiol (Berlin, Germany) or DxS Diagnostic Innovations (Manchester, UK) kits. In frozen tissue samples, concordance in KRAS status (defined as consensus in at least five assays) was observed in 66/80 (83%) cases. In paraffin tissue, concordance was 46/74 (63%) if all assays were considered or 71/74 (96%) using the five best performing assays. These results demonstrate that a variety of detection methodologies are suitable and provide comparable results for KRAS mutation analysis of clinical samples
    Original languageEnglish
    Pages (from-to)543-552
    JournalJOURNAL OF MOLECULAR DIAGNOSTICS
    Volume11
    Issue number6
    DOIs
    Publication statusPublished - 2009

    Fingerprint Dive into the research topics of 'A multicentre blinded study to evaluate KRAS mutation testing methodologies in the clinical setting'. Together they form a unique fingerprint.

    Cite this